Crinetics Reports Fourth Quarter and Full Year 2022 Financial Results


Crinetics Pharmaceuticals reported financial results for the fourth quarter and year ended December 31, 2022

Crinetics Announces February 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces February 2023 inducement grants: the stock options were granted as inducements material to six employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference


Crinetics Pharmaceuticals will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference on February 14, 2023.

Crinetics Announces January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces January 2023 inducement grants: the stock options were granted as inducements material to six employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference


Crinetics provides a company update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 3:00 p.m. Pacific Time